Add us as a preferred source
The latest investment rounds, grants, and strategic partnerships in healthtech, medtech, and life sciences, featuring healthcare staffing, blood screening and in vivo cell therapy.
RM Medics secures £800,000 funding package from Praetura
Bedford-based healthcare recruitment and clinical insourcing specialist RM Medics has secured an £800,000 funding facility from SME lender Praetura. The working capital facility will support the business as it bids for new NHS clinical insourcing contracts, invests in new technology and scales its internal recruitment team.
Founded to help healthcare providers manage staffing shortages and reduce patient waiting times, RM Medics supplies locum doctors and temporary healthcare professionals, alongside complete insourced clinical teams capable of deploying within two to four weeks. These teams deliver weekend and bank holiday sessions across surgery, diagnostic imaging, endoscopy, and outpatient care to increase NHS capacity using existing hospital infrastructure.
“NHS teams are under sustained pressure to meet demand and reduce waiting lists, but adding capacity cannot come at the expense of quality or continuity of care,” said Mohammad Mohson, director at RM Medics. “Praetura’s support gives us the financial flexibility to pursue new clinical insourcing opportunities and continue supporting NHS and private healthcare providers across the UK.”
Emerald raises £1.4 million
London-based preventative healthcare platform Emerald has raised £1.4 million in a new funding round, bringing its total capital raised to date to £2.9 million.
The financing comprises a £700,000 grant from Innovate UK alongside £700,000 in venture capital investment. The equity round was backed by existing investor Boost Capital Partners, with participation from new backers Sequel and Highgoal Capital.
Launched in 2024, Emerald combines in-clinic blood screening with a digital platform that aggregates lab results, wearable data, and health history. Registered with the CQC and authorised as a UKCA Class I medical device with the MHRA, the platform pairs users with dedicated GPs for diagnosis, prescriptions and referrals across private and NHS care.
The business will deploy the capital to scale its commercial partnerships across the employee benefits, fintech and fitness sectors – including existing arrangements with Pluxee, Epassi and Yonder – and intends to hit one million members over the next three years. The Innovate UK grant will specifically fund the expansion of Emerald’s AI capabilities for proactive care delivery.
“A preventative approach to healthcare significantly improves long-term health outcomes by providing a more holistic view of a patient’s health, highlighting potential issues before they become critical, and empowering people to enter the right pathway earlier,” said Alexander Badalyan, co-founder and chief executive of Emerald. “This additional funding allows us to build on the demand we’re already seeing, deepen these partnerships, and expand care.”
Silvia Bio secures £3 million seed round
University of Sheffield spinout Silvia Bio has secured £3 million seed funding led by Northern Gritstone, with participation from the Parkwalk Northern Universities Venture Fund, the UK Innovation & Science Seed Fund (managed by Future Planet Capital), Wren Capital and angel investors.
Silvia Bio tackles yield bottlenecks in producing biological therapeutics, such as antibodies and gene therapies. The company’s integrated cell-profiling platform generates a detailed biological fingerprint of underperforming mammalian cell cultures to identify manufacturing bottlenecks, then formulates licensable, bioreactor-compatible media additives designed to improve yields and product quality.
The capital will support Silvia Bio’s transition from university premises into dedicated laboratory facilities at the Innovation Centre in Sheffield, alongside investments in process automation, team expansion and international commercialisation.
“The medicines being developed today have the potential to transform patients’ lives, but many are becoming harder and more expensive to manufacture,” said Ed Curry, co-founder and chief executive of Silvia Bio. “Our platform gives biopharmaceutical companies a much clearer view of why their cells are underperforming and, crucially, provides practical solutions that can be introduced directly into the manufacturing process. This investment will allow us to automate and scale our technology, grow our team and help more companies bring complex medicines to patients faster.”
Cori Clinical closes $4 million seed round
London-based clinical trial intelligence platform Cori Clinical has closed a $4 million (£3 million) seed funding round led by venture capital firm Breega, with participation from Enzo, Heartfelt, Together Ventures and Bynd.
The company will use the capital to expand product delivery, strengthen platform intelligence and scale its commercial operations with pharmaceutical sponsors and contract research organisations (CROs).
Cori Clinical provides a unified AI workspace that integrates an organisation’s historical trial data with external intelligence from registries and regulatory authorities, including the FDA, MHRA and EMA. The platform connects trial briefs with protocols, regulatory submission packages and operational plans, helping clinical teams identify design risks before protocols are finalised. The company has also appointed former Lindus Health executive Emma Ogburn as chief clinical officer to lead its clinical strategy.
“Clinical trials are built through a series of interconnected decisions about how a study should be designed and run,” said Jorn Jansen Schoonhoven, co-founder and chief executive of Cori Clinical. “Cori brings that intelligence together into a living blueprint, so teams can make better-informed decisions before avoidable problems become delays, so the science never waits on the process.”
Sava raises $36 million Series B
London-based healthtech startup Sava Technologies has raised $36 million (£27 million) in a Series B funding round led by global diabetes care specialist Ascensia Diabetes Care. The round includes participation from existing investors Balderton Capital, Norrsken VC, Simplyhealth Ventures, JamJar Investments and Pentland Ventures, lifting Sava’s total funding to $68 million.
Alongside the investment, Sava signed a commercialisation and distribution agreement appointing Ascensia, a subsidiary of PHC Holdings Corporation, as its distribution partner across Europe.
Founded in 2019, Sava has developed a wearable continuous glucose monitor built on proprietary microsensor technology. Designed to measure molecules in interstitial fluid just beneath the skin painlessly, Sava’s sensors are roughly ten times shorter than conventional continuous glucose monitor filaments.
Sava will use the capital to scale manufacturing capabilities ahead of a planned pivotal clinical trial. The company is targeting CE mark approval for non-adjunctive use within 18 to 24 months, enabling patients to make insulin dosing decisions without routine fingerstick testing. Following regulatory clearance, Ascensia will lead the European commercial launch.
“For decades, continuous monitoring has been held back by the same legacy technology,” said Renato Circi, co-founder and co-chief executive of Sava. “This is about to change.”
Siloton awarded £8.4 million Innovate UK contract
Bristol-based medtech startup Siloton has been awarded an £8.4 million commercial contract from Innovate UK, part of UK Research and Innovation (UKRI), under its Contracts for Innovation: Quantum Missions Primer initiative. Delivered over two years, the non-dilutive funding will accelerate clinical development and manufacturing preparation for both in-clinic and at-home versions of its handheld optical coherence tomography (OCT) eye imaging system, GiraffeOCT.
Siloton compresses traditional, hospital-grade OCT imaging components onto a small single photonic chip. The device aims to decentralise retinal disease monitoring into primary care and home settings.
As part of the two-year contract, Siloton will partner with Sunderland Specialist Eye Hospital on clinical trials for its in-clinic system, with the York Health Economics Consortium gathering health economic data to validate potential cost savings for the NHS. It is also working with the University College London Great Ormond Street Institute of Child Health to modify one system for children’s use.
Siloton expects the award to shorten its product development timeline by up to two years and plans to leverage the contract to raise an equity funding round to support its second-generation retinal imaging device, CheetahOCT.
“Winning this Innovate UK contract allows us to accelerate the development of our systems, explore manufacturing and assembly in the UK, and help a groundbreaking new technology be adopted by the NHS more quickly,” said Alasdair Price, chief executive of Siloton.
Basecamp Research raises $140 million Series C
London and Boston-based frontier AI biotech Basecamp Research has closed a $140 million (£106 million) Series C funding round led by S32, with backing from NVIDIA, Menlo Ventures’ Anthology Fund, Catalio Capital Management, NATO Innovation Fund, European Tech Collective, Firebrand River Capital, Inception Fund, King Philanthropies, PostScriptum, Redalpine, The Rockefeller Foundation, Singular, Sovereign AI and True Ventures. Individual investors included André Hoffmann, vice-chairman of Roche.
Basecamp Research develops AI-designed medicines built on EDEN, its biological foundation model trained on the Trillion Gene Atlas – a genomic dataset collected through access and benefit-sharing partnerships across more than 30 countries. The company combines EDEN’s generative DNA design with large serine recombinase technology to reprogramme a patient’s cells inside the body to treat cancer, autoimmune conditions and genetic diseases.
The capital will fund the development of new EDEN foundation models, advance its internal pipeline of AI-designed therapeutics toward clinical trials, and support the expansion of pharmaceutical industry partnerships, led by newly appointed chief business officer Richard Pearce (formerly of Biogen). Former Verily chief executive and S32 general partner Andy Conrad will also join the board of directors.
“We believe the future of medicine lies in reprogramming the body to repair itself. We design the models and the medicines to teach it how,” said Glen Gowers, co-founder and chief executive of Basecamp Research. “AI-based approaches promise to change what’s possible for patients who currently have few alternatives. This funding brings this technology closer to those who need it most.”
OMass Therapeutics raises $310 million Series C
Oxford-based biotechnology company OMass Therapeutics has closed an oversubscribed $310 million (£230 million) Series C financing round. The investment was co-led by new investors Bain Capital Life Sciences, Forbion and Novo Holdings, alongside participation from Janus Henderson Investors, SV Health Investors and Jefferson Life Sciences. Existing backers Syncona, Oxford Science Enterprises, GV, Northpond Ventures, Sanofi Ventures, British Business Bank and the University of Oxford also participated.
A spinout from the University of Oxford, OMass focuses on small molecule therapeutics which target complex membrane proteins and target ecosystems. Proceeds from the financing will support Phase 2 clinical trials for its lead program, OMS1620, a selective melanocortin-2 (MC2) receptor antagonist designed for congenital adrenal hyperplasia (CAH) and ACTH-dependent Cushing’s syndrome. The capital will also fund early clinical development for its potential first-in-class SLC15A4 inhibitor for lupus and other autoimmune conditions.
In connection with the funding round, Evan Greif of Bain Capital Life Sciences and Audrey Cacaly of Forbion will join the OMass board.
“This financing comes at an exciting point in OMass’ evolution as we advance OMS1620 into the clinic, with our SLC15A4 inhibitor poised to follow,” said Ros Deegan, chief executive officer of OMass Therapeutics. “We have demonstrated the ability of our team and approach to discover and deliver a pipeline of first- and best-in-class programs in endocrinology and immunology into the clinic.”
